Nature CommunicationsGeneticsPeer-reviewed journal article
Evaluating transportability of in-vitro cellular models to in-vivo human phenotypes using gene perturbation data
Laurence J HoweiD, Yurii S. AulchenkoiD, George Davey SmithiD, Neil M DaviesiD, Jorge Esparza-Gordillo, Toby JohnsoniD, Jimmy Z. LiuiD, Tom G. RichardsoniD, Philippe Sanséau, Robert A. ScottiD, Daniel D. SeatoniD, Ashwini Kumar SharmaiD, Adrián CortésiD
Abstract
Gene perturbation screens (e.g. CRISPR-Cas9) assess the impact of gene disruption on in-vitro cellular phenotypes (e.g., proliferation, anti-viral response, transcriptomics). In-vitro experiments can be useful models for understanding the aetiology of in-vivo (organismal) phenotypes. For example, anti-viral response in immune cells and infectious disease outcomes. However, assessing whether an in-vitro cellular model is effectively capturing in-vivo biology is challenging. An in-vitro model is transportable to an in-vivo phenotype of interest if perturbations impacting the in-vitro phenotype also impact the in-vivo phenotype with mechanism-consistent directionality and effect sizes. We propose a framework; Gene Perturbation Analysis for Transportability (GPAT), to assess model transportability using gene perturbation effect estimates from perturbation screens (in-vitro cellular phenotypes) and loss-of-function burden tests (in-vivo phenotypes). Using UK Biobank whole-genome sequence data and data from published genome-wide CRISPR-Cas9 screens, we evaluated transportability of in-vitro cellular models to in-vivo human phenotypes. In hypothesis-driven analyses, we found evidence that higher lysosomal cholesterol accumulation in-vitro is a transportable model for lower LDL-cholesterol measured in human blood plasma (P = 0.0006), consistent with the known role of lysosomes in lipid biosynthesis. In contrast, we found limited evidence for other putative in-vitro models. In hypothesis-free analyses, we found strong evidence for transportability of proliferation in cancer cell lines for in-vivo human plasma cellular phenotypes. For example, higher proliferation in an erythroleukemia cell line and lower plasma lymphocyte percentage. GPAT enables systematic evaluation of the transportability of in-vitro cellular models to in-vivo phenotypes, informing assay prioritization and supporting novel hypothesis generation.
- organism: human
- assay: CRISPR screen
- research focus: benchmarking
- research focus: gene regulatory network inference
- research focus: differential expression
- research focus: variant effect prediction
- approach: statistical model
- Citations
- 1
- FWCI
- 0.30
- Field percentile
- top 45%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differences between in vivo and ex vivo models drive divergent perturbation outcomes
Aarathy Ravi Sundar Jose Geetha, Cynthia del Valle, … Nikolaus Fortelny·bioRxiv·Sep 2, 2025
- Genetic Perturbation Prediction Models Fail Out-of-Distribution: A Rigorous Benchmark and Systematic Evaluation
Kanupriya Tiwari, Gaurang Mahajan, … Abhishek K Jha·bioRxiv·Oct 19, 2026
- Averaging in gene perturbation benchmarks hides perturbation-strength variation: Consequences for model evaluation
Yash Sharma, Madhav Subramaniyam, … Márió Szegedy·bioRxiv·Oct 23, 2026
- X-Cell: Scaling Causal Perturbation Prediction Across Diverse Cellular Contexts via Diffusion Language Models
Chloe Wang, Mehran Karimzadeh, … Bo Wang·bioRxiv·Mar 20, 2026
- In vitro to in vivo pharmacokinetic translation guidance
U. Fagerholm·bioRxiv·Sep 26, 2022
- pertTF: context-aware AI modeling for genome-scale and cross-system perturbation prediction
Yangqi Su, Dingyu Liu, … Wei Li·bioRxiv·Mar 16, 2026